# Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients

> **NCT03873987** · PHASE1 · COMPLETED · sponsor: **Melinta Therapeutics, Inc.** · enrollment: 102 (actual)

## Conditions studied

- Acute Bacterial Skin and Skin Structure Infection

## Interventions

- **DRUG:** Current Formulation of Oritavancin
- **DRUG:** Kimyrsa

## Key facts

- **NCT ID:** NCT03873987
- **Lead sponsor:** Melinta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-16
- **Primary completion:** 2019-08-27
- **Final completion:** 2019-09-04
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2021-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03873987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03873987, "Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03873987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*